Novavax Inc. (NASDAQ:NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results. It is worth noting that Novavax has a short interest of 31.41% of its float.Novavax Q4 Profit ShiftNovavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year.However, the compa ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Key Takeaways Novavax reported Q4 EPS of 11 cents, beating loss estimates as revenues rose 67% year over year.NVAX posted $108M in licensing revenues, including $98M under its Sanofi agreement.Novavax expects 2026 adjusted revenues of $230M-$270M, excluding Sanofi receivables.Novavax (NVAX) reported earnings of 11 cents per share in the fourth quarter of 2025 against the Zacks Consensus Estimate of a loss of 66 cents. In the year-ago quarter, the company had recorded a loss of 51 cents.Quarterly revenues to ...

来源：环球市场播报 诺瓦瓦克斯公司（纳斯达克股票代码：NVAX）周四股价上涨，此前该公司公布了2025年第四季度及全 年财务业绩。 每股收益 诺瓦瓦克斯报告第四季度每股收益为11美分，与去年同期每股亏损51美分相比实现扭亏。第四季度营收 为1.47亿美元，同比增长67%。 "随着2026年有一个强劲的开局，包括最近宣布的与辉瑞的Matrix-M协议，我们期待合作伙伴在商业和 临床开发方面的执行，推动我们的研发工作，并在我们利用技术推动疫苗创新和价值创造的过程中，期 待更多潜在的合作机会，"雅各布斯周四评论道。 业绩指引 诺瓦瓦克斯强调了2026年的营收预测，预计调整后总营收在2.3亿至2.7亿美元之间，而市场普遍预期为 3.8122亿美元。 公司预计实现Nuvaxovid产品销售额3500万至4500万美元，以及调整后供应销售额4000万至5000万美 元，这反映了与血清研究所等合作伙伴的持续合作。 技术分析 目前，该股交易价格较其20日简单移动平均线（SMA）高出8.4%，较其100日SMA高出9.2%，显示出短 期强势。在过去12个月中，股价大幅上涨，目前更接近其52周高点而非低点，反映出强劲的上升趋势。 ...

Novavax Inc. (NASDAQ:NVAX) shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results.EarningsNovavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase.Novavax on Thursday said it beat its 2025 cost-cutting targets across both GAAP and Non-GAAP R&D and SG&A spending and is tightening future expense goals.The company now expects N ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Welcome to Novavax Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your touchtone phone. To withdraw your qu ...

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals Earlier this month, the U.S. Food and Drug Administration initially refused to review rival Moderna's (MRNA.O), opens new tab mRNA-based flu vaccine, then reversed course a week later after the company amended its application. The biotech now expects 2026 adjusted revenue of $230 million to $270 million, up from its prio ...